Q-omics provides the consensus-scored MIA-RAB4B profile across patient tissues and cancer cell-line models. MIA-RAB4B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MIA-RAB4B is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, MIA-RAB4B RNA expression shows 8,494 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, BRCA, and TGCT as cancer lineages where MIA-RAB4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIA-RAB4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIA-RAB4B survival associations across molecular data types. MIA-RAB4B RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIA-RAB4B RNA expression–survival associations across cancer types. High MIA-RAB4B expression shows unfavorable associations in KIRP, LIHC, KIRC, DLBC and LGG, but favorable associations in CHOL. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MIA-RAB4B RNA expression.
This table summarizes MIA-RAB4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIA-RAB4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIA-RAB4B shows lower tumor expression in BRCA, HNSC and COAD and higher tumor expression in STAD and LUSC. The BRCA box plot shows higher MIA-RAB4B RNA expression in normal versus tumor tissue (log2 FC = −0.140, t-test p < 0.001).
This table shows molecular features associated with MIA-RAB4B in patient tissues and cancer cell lines. In patient samples, MIA-RAB4B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MIA-RAB4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN.
